Metoprolol Injection
NDC Package 83270-177-10
Package Information
Metoprolol (metoprolol tartrate injection) injection is metoprolol Tartrate Injection, USP is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. This formulation utilizes a injection delivery system. Marketed by Oneosource Specialty Pharma Limited, this product is identified by NDC 83270-177 and is authorized under FDA application ANDA090317.
Identification & Billing
- RxCUI: 866508 - metoprolol tartrate 5 MG in 5 ML Injection
- RxCUI: 866508 - 5 ML metoprolol tartrate 1 MG/ML Injection
- RxCUI: 866508 - metoprolol tartrate 5 MG per 5 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 83270 - Oneosource Specialty Pharma Limited
- 83270-177 - Metoprolol
- 83270-177-10 - 10 VIAL in 1 CARTON / 5 mL in 1 VIAL (83270-177-01)
- 83270-177 - Metoprolol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83270-177-10 identifies a specific commercial package of 10 vial in 1 carton / 5 ml in 1 vial (83270-177-01) of Metoprolol, a human prescription drug labeled by Oneosource Specialty Pharma Limited. This injection is formulated for intravenous use and contains metoprolol tartrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Oneosource Specialty Pharma Limited on April 30, 2026. The current certification is valid through December 31, 2027.
How is this Oneosource Specialty Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83270017710. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.